Journal · Our own computation

The pharmacy disclosure gap: the question no provider answers

One question decides whether a GLP-1 provider's supply chain can be checked at all: which pharmacy fills your prescriptions, and is it a 503A pharmacy or a 503B outsourcing facility? Across all 20 providers we track, the number of complete answers in the public record is 0. This piece quantifies that gap, is precise about what it does and does not prove, and traces what it costs consumers — and scores.

The count

Why this one field

Because it is where the physical product comes from, and because federal policy is actively sorting compounders into categories with different futures. The FDA hasproposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list; whether a patient's supply runs through a 503B outsourcing facility or a 503A pharmacy determines their exposure to that decision. A patient who doesn't know which kind of facility fills their prescription cannot assess their own supply-continuity risk, cannot look the facility up in the FDA's public registers, and cannot check its state licensure — every verification path starts from a name, as ourverification guide shows in practice.

The one partial answer on record illustrates the gap between class and name.NexLife states it uses U.S.-licensed 503A compounding pharmacies — a provider-reported claim we display with exactly that label — but without a named pharmacy the claim is uncheckable: no register lookup, no license verification, no inspection history. A class claim is a start; it is not traceability.

The scoring consequence

Our rubric allocates 15 of 100 points to pharmacy traceability and quality disclosure, and the register extends the same logic to three further disclosure categories — clinical continuity, state coverage, and cancellation terms — that together lock55 of the 100 points, leaving only 45 scorable from public information today. The caps bind hard: with the pharmacy field unscorable for every provider, the maximum achievable score is 50, and no provider can reach the band a fully transparent operator would occupy. We consider that outcome correct, not unfortunate. A ranking system that quietly routed around the most consequential undisclosed fact — as most "best GLP-1" listicles do — would be laundering opacity into stars. The cap converts the market's opacity into a visible, market-wide penalty that any single provider can escape unilaterally, by disclosing.

The standing questions

The disclosure programme recorded in our dataset opened on 2026-07-26 and defines four questions to be put to every covered provider in identical terms. Its register currently marks every provider "not yet asked" — so, again precisely: today's gap describes the public record, and becomes attributable silence only after a provider receives the questions and declines. The pharmacy question reads: "Which pharmacy or pharmacies fill prescriptions written through your programme, and is each registered as a 503A compounding pharmacy or a 503B outsourcing facility?"

Answers, when they arrive, will be published on the pharmacy disclosure board with a provider-reported label and a capture date, and the answering provider's categories unlock in our scoring. Providers can answer at any time through theright-to-respond process. The register — questions, rationale, and per-provider status — is public precisely so the gap stays measurable in both directions.

Method

Counts are computed at build time from providers.json using the sameisPharmacyNamed() rule the provider pages use, so this piece can never disagree with the disclosure lines rendered on those pages. "No public statement on record" means our dataset holds no disclosure — it is a statement about the public record we could find, not proof the provider has never said anything anywhere. If you operate one of these providers and have a public pharmacy disclosure we missed, the corrections process will get it recorded, labeled, and counted within this analysis on the next build.